SVB Securities analyst Thomas Smith reiterated a Buy rating on Connect Biopharma Holdings (CNTB – Research Report) on July 12. The company's shares closed last Wednesday at $0.92, close to its 52-week low of $0.56. According to TipRanks.com, Smith has 0 stars on 0-5 stars ranking scale with an average return of -26.3% and a 20.7% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Prometheus Biosciences, and Eledon Pharmaceuticals. Connect Biopharma Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $3.25.
https://www.tipranks.com/news/blurbs/svb-securities-thinks-connect-biopharma-holdings-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Connect Biopharma Charts.
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Connect Biopharma Charts.